Leveraging the capabilities of Realyze Intelligence technology, a group of researchers from UPMC Hillman Cancer Center, Institute for Precision Medicine, & University of Pittsburgh have published in JAMA Surgery. The study shows how real-world-data-led insights improve breast cancer patient care.

Realyze Intelligence technology has powered a groundbreaking research study that will inform more personalized care pathways and improve the quality of life for breast cancer patients. The research was published today in the
Journal of Clinical Oncology Clinical Cancer Informatics, an American Society of Clinical Oncology (ASCO) journal.

A poster, presented today, Thursday, April 9, 2024, at the American Association for Cancer Research Annual Meeting, (AACR Annual Meeting) demonstrated that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) successfully applied machine learning (ML) and large language models (LLM) to augment the manual curation of cancer data elements using the Realyze Intelligence platform. 

Realyze Intelligence has earned a position among the inaugural class of start-up companies selected for the CancerX Startup Accelerator, part of the Biden administration Cancer Moonshot program that aims to cut the U.S. cancer death rate in half within the next 25 years.